awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q30249790-0DB59F8B-AEF0-4E4D-B747-81C2AE094197
Q30249790-0DB59F8B-AEF0-4E4D-B747-81C2AE094197
BestRank
Statement
http://www.wikidata.org/entity/statement/Q30249790-0DB59F8B-AEF0-4E4D-B747-81C2AE094197
Are maintenance and continuous therapies indicated for every patient with multiple myeloma?
P2860
Q30249790-0DB59F8B-AEF0-4E4D-B747-81C2AE094197
BestRank
Statement
http://www.wikidata.org/entity/statement/Q30249790-0DB59F8B-AEF0-4E4D-B747-81C2AE094197
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
046b35ca13d926a09bf3c56c047f9368af6f03e2
P2860
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.